Inovio has secured funding from the U.S Department of Defense to expedite the development and production of its Cellectra 3PSP Smart Devices for the administration of the COVID-19 vaccine. INO stock is up.
In the last three months, INO has pulled in more than 181% returns. For 2020, Inovio (INO) investors have seen 233.33% returns.
Inovio (INO) stock was jumped 8% yesterday, is in the green now after the company released its fiscal Q1 earnings report, while it is working on a coronavirus vaccine.
Moderna Inc proceeds ahead for the Phase 2 clinical trial of its vaccine to fight with the coronavirus. The company has received a nod from the Food and Drug Administration to proceed ahead with the project. MRNA stock is in the green in the pre-market.
Novavax (NVAX) stock climbed 25% yesterday, adding to its current 2020 gains, as the company makes progress on its COVID-19 vaccine candidate. However, today NVAX is 14% down.
As of the market closed on Monday, shares of Inovio Pharmaceuticals (INO) were up by 9.6%, while Moderna (MRNA) rose 10.3%. Novavax (NVAX) blasted higher by 24.7%, and VBI Vaccines (VBIV) posted a comparable 24.2% gain.
Inovio Pharmaceuticals alongside Moderna are edging close to providing a vaccine for the novel coronavirus. However, Inovio (INO) stock is down these days.
Coronavirus has already claimed the lives of many people. At least 16,703 people in the U.S. have died. In Spain, this number is 15,843. In France, the death toll is 12,210. The statistics are dismaying. We need the vaccine as soon as possible.
Inovio stock has been swung significantly in the last 24 hours after rising on news of a new grant and plunging on news of its poor Q4 report.
Citron Research warned investors that Ino stock would fall back to $2 and called for the Securities and Exchange Commission to investigate Inovio and suspend trading of its stock.
Inovio (INO) stock has now erased some of its YTD gains after Citron Research suggested the company was grandstanding. Citron’s analysts now put INO at $2.
Dow Jones has lost over 1,880 points due to a row of factors including Saudi’s oil price slash as well as the coronavirus that is quickly spreading. More bleeding is expected.
At the moment, Inovio (INO) is probably the best performing stock among the biotech companies, with over 300% gains. Let’s take a look at the reasons why this is so.
Inovio(INO) stock is enjoying the rally as it put on almost 8% weight days after it announced that it will be speeding up plans for its coronavirus (COVID-19) vaccine.
Inovio plans to start a clinical trial of its coronavirus vaccine in the U.S. next month with the thought to expand to China and South Korea shortly thereafter.